I stumbled across this thread and am interested in the fact that you are developing rapid result medical diagnostic test kits. As I am sure you are aware there is another company (which I am a shareholder of) - Response Biomedical (RBM.VSE) which is about to launch a revolutionary point-of-care diagnostic science which has applications for over 200 medical tests, plus food and environmental testing. It is low cost, quantitative, accurate, low development time ...... and there is no competition in sight. They already have two major partners, strong management and are getting ready to produce in December.
How does your science compare from a technical, practical and financial perspective? Why is your company a better investment?
Here is Response's website response-bio.com
and here is a small exerpt from the website:
"Point-of-care immunoassays have remained incapable of precise, highly sensitive, quantitative measurement. RAMP offers a solution with rapid, sensitive, quantitative results.
The essence of the RAMP technology lies in its ability to detect concentrations of latex particles, carriers for the antibody, and accurately quantify the amount of latex present by utilizing proprietary chemistry and optics. This breakthrough technology permits the development of assays which give the quantitative results characteristic of large, laboratory systems while retaining the inherent low cost, simplicity and portability of point-of-care immunoassays.
The RAMP Difference
The RAMP system consists of two components: a disposable cartridge which houses an immunochromatographic assay and a portable fluorescence reader to quantify antibody-antigen complexes.
Four distinct features give RAMP an edge in diagnostic testing and the ability to respond quickly to new market opportunities:
High Sensitivity. The proprietary chemical and optical methods used in the RAMP system virtually eliminate the optical interference of the membrane, dramatically improving the signal obtained from the fluorescently dyed latex. The resulting improvement in sensitivity allows assays to be performed over the same range of analyte concentration as laboratory based immunodiagnostic procedures such as ELISAs.
Low Manufactured Cost. The manufactured cost of the disposable cartridge will be less than $1 and the projected manufactured cost of the RAMP Reader is approximately $1000.
Short Development Time for New Analytes. A mathematical model has been developed which accurately predicts the behavior of RAMP assays, including the amount of antigen which will bind to the latex and the optical signal produced by latex arrested in the detection zone. The model provides guidelines for initial parameter selection and assay development, reducing the time required to develop a working assay to a six-month period. Given the ready availability of highly specific, commercially available antibodies, Response is able to respond quickly to market opportunities and develop tests for a wide range of routinely measured analytes.
Small Molecules. Response believes that the RAMP technology can be applied to all immunogenic analytes, including those with a single epitope. This would allow Response to develop tests for analytes which have a low molecular weight, such as therapeutic drugs and hormones. "
Thanks in advance for your reply,
Rob |
